Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BRAF(V600E) kinase is a mutant form of the B-Raf protein, a serine/threonine-specific protein kinase. The V600E mutation results in constitutive activation of the kinase, leading to continuous downstream signaling through the MAPK/ERK pathway, promoting uncontrolled cell proliferation and survival. It is a significant oncogenic driver and therapeutic target in several cancers, including melanoma, colorectal cancer, and thyroid carcinoma.
Inhibition of BRAF(V600E) kinase activity, leading to decreased MAPK/ERK pathway signaling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BRAF V600E Kinase (BRAF(V600E)).